Venous thrombosis (VT) affects over 1 million Americans annually. Even with treatment, 30-50% of VT patients develops recurrent VT or suffer debilitating long-term morbidity including chronic pain, edema, and ulcers (so- called post-thrombotic syndrome). Current anticoagulation therapies target factor Xa or thrombin and are associated with a significant risk of catastrophic bleeding. The development of next generation agents which reduce thrombosis without increasing the risk of hemorrhage, would have a profound impact on this significant clinical problem. The defining characteristics of venous red thrombi are their high red blood cell (RBC) and fibrin content. The existing paradigm suggests RBCs are passively trapped in the clot during fibrin polymer formation. However, we have recently discovered that factor XIII (FXIII) mediates RBC retention in clots and determines clot size. We have also identified fibrinogen residues that promote interactions with FXIII and are required for normal FXIII activation and fibrin crosslinking. Importantly, we have shown that inhibiting FXIIIa activity or blocking FXIII-fibrinogen interactions reduces clot RBC content, and consequently, significantly reduces thrombus size in vitro and in vivo. These exciting discoveries suggest that inhibiting FXIII or blocking FXIII-fibrinogen interactions represent entirely new and novel strategies for reducing VT. The goal of this application is to determine the molecular mechanisms by which FXIII and fibrinogen mediate VT. The overall hypothesis is that FXIII(a) activity mediates RBC retention in clots. Thus, inhibiting FXIII activiy or disrupting the interaction between FXIII and fibrinogen will reduce VT. This hypothesis will be tested in three Specific Aims: 1) Define the fibrinogen residues required for FXIII binding and determine whether peptides that disrupt FXIII interactions with fibrinogen decrease RBC retention in clots, 2) Determine whether FXIIIa promotes RBC retention in clots via fibrin crosslinking, and 3) Determine the role of FXIII and effect of FXIII(a) inhibition in VT and hemostasis. This study will employ biochemical, genetic and pharmacologic tools to define the FXIII- fibrinogen axis and determine the role of FXIII activity and RBC retention during whole blood clot formation. FXIII-fibrinogen interactions and FXIIIa function will be examined using recombinant proteins, solution phase binding assays, and innovative fibrin analytical methods. Clot formation will be studied using in vitro and in vivo models of VT and hemostasis, including live-animal imaging (e.g., ultrasound imaging and intravital microscopy). These studies will significantly expand our understanding of newly-recognized roles for FXIII(a) and fibrinogen in thrombus formation and stability. This study is highly innovative because it challenges the current paradigm that RBCs are passively entangled in thrombi and proposes that thrombus RBC content can be reduced to prevent VT. The proposed research is clinically significant because it may reveal an entirely new strategy to reduce VT.

Public Health Relevance

The proposed research is relevant to public health because it will reveal information about a previously unrecognized mechanism that mediates venous thrombosis. Specifically, the work focuses on factor XIII, fibrinogen, and the incorporation of red blood cells in venous thrombi, and how red blood cell incorporation in thrombi may be reduced to prevent venous thrombosis. The project is relevant to NIH's mission to expand the medical knowledgebase to reduce the burden of human disease.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Warren, Ronald Q
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Schools of Medicine
Chapel Hill
United States
Zip Code
Byrnes, James R; Wolberg, Alisa S (2017) Red blood cells in thrombosis. Blood 130:1795-1799
Gebhart, Johanna; Kepa, Sylvia; Hofer, Stefanie et al. (2017) Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause. Ann Hematol 96:489-495
Byrnes, James R; Wolberg, Alisa S (2017) New findings on venous thrombogenesis. Hamostaseologie 37:25-35
Dargaud, Y; Wolberg, A S; Gray, E et al. (2017) Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 15:1704-1707
Kattula, Sravya; Byrnes, James R; Wolberg, Alisa S (2017) Fibrinogen and Fibrin in Hemostasis and Thrombosis. Arterioscler Thromb Vasc Biol 37:e13-e21
Bagoly, Zsuzsa; Ariƫns, Robert A S; Rijken, Dingeman C et al. (2017) Clot Structure and Fibrinolysis in Thrombosis and Hemostasis. Biomed Res Int 2017:4645137
Walton, Bethany L; Lehmann, Marcus; Skorczewski, Tyler et al. (2017) Elevated hematocrit enhances platelet accumulation following vascular injury. Blood 129:2537-2546
Byrnes, James R; Wilson, Clare; Boutelle, Anthony M et al. (2016) The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen residues ?390-396 and the FXIII-B subunits. Blood 128:1969-1978
Byrnes, James R; Wolberg, Alisa S (2016) Newly-Recognized Roles of Factor XIII in Thrombosis. Semin Thromb Hemost 42:445-54